Cervical Cancer and HPV Research
Research Guide

Human papillomavirus is a necessary cause of invasive cervical cancer worldwide, with 93% of cases containing HPV DNA. Walboomers et al. (1999) in 'Human papillomavirus is a necessary cause of invasive cervical cancer worldwide' confirmed this through PCR-based testing across global samples. This establishes HPV as the primary etiologic agent.

HPV types 16 and 18 are the most common, with types 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68, 73, and 82 classified as carcinogenic, and types 26, 53, and 66 as probably carcinogenic. Muñoz et al. (2003) in 'Epidemiologic Classification of Human Papillomavirus Types Associated with Cervical Cancer' derived this from epidemiologic data. These high-risk types drive most cervical carcinomas.

The E6 oncoprotein from HPV types 16 and 18 promotes p53 degradation, disrupting cell cycle control. Scheffner et al. (1990) in 'The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53' demonstrated this mechanism. This inactivation enables viral persistence and carcinogenesis.

Cervical cancer contributes significantly to worldwide cancer statistics, with estimates from GLOBOCAN showing rising incidence due to population growth and risk behaviors. Jemal et al. (2011) in 'Global cancer statistics' reported 12.7 million total new cases in 2008. Arbyn et al. (2019) provided 2018 incidence and mortality estimates worldwide.

Cytology screening detects precancerous lesions associated with HPV. The field covers HPV testing and self-sampling as secondary prevention tools. Recent efforts accelerate integration of HPV testing and thermal ablation, per news on cervical cancer elimination.

HPV vaccination prevents cervical cancer and pre-cancerous changes, especially in unvaccinated populations through herd immunity. New research confirms effectiveness in over 857,000 girls. Cochrane reviews provide strong evidence for vaccines given before exposure.